The 4-Domain Protocol:
A Biomarker-Guided, Phenotype-Specific Clinical Decision Framework for Chronic Pain Management

An Introduction to the 4-D Protocol for the Management of Chronic Pain

The development of the 4-D Protocol — "A Four-Domain Approach for the Management of Chronic Pain, Including the Use of Nutraceuticals" — originated from a fundamental clinical observation: the anti-inflammatory diet (AID) offers measurable benefits for chronic pain management that extend well beyond its established role in cardiovascular health and metabolic disease prevention.[1][2][3] A systematic review with meta-analysis by Field et al. (2021) confirmed a significant overall effect of whole-food dietary interventions on pain reduction across 43 studies, with no single dietary approach standing out as superior — suggesting that the commonalities among anti-inflammatory dietary patterns (diet quality, nutrient density, anti-inflammatory compound content) are what modulate pain physiology.[4] This evidence raised a critical question: if the foods that constitute the anti-inflammatory diet contain bioactive compounds with demonstrated analgesic and anti-inflammatory properties, could those specific compounds — isolated, dosed, and targeted — be deployed as nutraceutical interventions guided by an individual patient's biochemical profile?

In examining the AID, specific bioactive compounds found in its constituent foods were identified and selected for inclusion in the protocols based on the quality of evidence supporting their benefits in chronic pain management. These compounds include omega-3 polyunsaturated fatty acids (from fish and seafood), curcuminoids (from turmeric), flavonoids and polyphenols (from fruits and vegetables), magnesium, B vitamins, and coenzyme Q10 — each with established mechanisms of action relevant to pain pathophysiology.[5][6] The Dietary Inflammatory Index (DII), which quantifies the inflammatory potential of dietary patterns based on their effects on IL-1β, TNF-α, IL-4, and IL-6, provided a validated framework for understanding how dietary constituents modulate the same inflammatory pathways measured by the protocol's laboratory biomarkers.[5]

From this foundation, four pathogenic domains — systemic inflammation, neuroinflammation, oxidative stress, and mitochondrial dysfunction — were identified as the primary biochemical drivers contributing to the severity and chronification of chronic pain. These domains were not selected arbitrarily; they represent the convergent pathways through which diet, lifestyle, and endogenous biochemistry interact to amplify or attenuate the pain experience.

The Distinction Between Pain Condition and Pain Processing

A central insight underlying the 4-D Protocol is the recognition that the primary goal of chronic pain management should be to reduce the severity of pain — not simply to focus on the assessment and management of the condition(s) responsible for generating nociceptive input. Conventional approaches to chronic pain tend to focus on the pain condition itself (e.g., osteoarthritis, disc herniation, neuropathy) and on interventions designed to impact that condition to reduce its contribution to the pain experience. This condition-focused approach, while necessary, is incomplete.

The severity of the pain experience is also profoundly influenced by **pain processing** — the complex cascade of neural events that occurs largely independent of the pain condition itself. From the moment a nociceptor is activated in the presence of tissue damage, signals travel along peripheral nerves to the spinal cord, where they interact with interneurons, glial cells, and descending modulatory pathways before being transmitted to the brain. At the brainstem level, the periaqueductal gray (PAG) and rostral ventromedial medulla (RVM) serve as critical relay stations in the descending

pain modulation system, which can either suppress or amplify nociceptive transmission depending on the balance of facilitatory and inhibitory inputs.[7][8][9] In the brain, pain signals interact with cortical, limbic, and prefrontal regions that integrate sensory, emotional, and cognitive dimensions of the pain experience. Ultimately, descending modulatory pathways — predominantly noradrenergic and serotonergic — project back to the spinal cord to further modulate pain signaling, either suppressing or magnifying the experience of pain.[9][10]

Chronic pain is now understood to be associated with dysfunction of these descending modulatory systems. Patients with chronic low back pain demonstrate a dysregulated PAG, with decreased excitatory (glutamatergic) and increased inhibitory (GABAergic) neurotransmission, resulting in impaired descending pain inhibition.[11] Chronic knee pain disrupts the normal relationship between autonomic nervous system activity and conditioned pain modulation, suggesting that pain chronification itself impairs the endogenous pain control system.[12] These findings position pain processing dysfunction not as a secondary consequence of chronic pain, but as an active driver of pain severity that operates alongside — and often independently of — the underlying pain condition.

This distinction has profound therapeutic implications. If pain severity is determined not only by the pain condition but also by the state of pain processing pathways, then interventions that modulate pain processing — by reducing neuroinflammation, restoring neurotransmitter balance, correcting oxidative stress, and improving mitochondrial function — can reduce pain severity even when the underlying condition remains unchanged. This is precisely the therapeutic rationale of the 4-D Protocol.

The Concept of Individualized Domain Profiling

Of key importance in the conceptual foundation of the 4-D Protocol is the recognition that each individual patient is impacted by all four pathogenic domains, but the relative contribution of each domain to a given patient's pain experience is unique. One patient may have a predominantly inflammatory phenotype with elevated hs-CRP and IL-6, driven by physical inactivity and a pro-inflammatory diet, while another may have a predominantly neuroinflammatory phenotype with elevated kynurenine pathway metabolites, driven by chronic sleep disruption and psychological stress. A third patient may present with significant mitochondrial dysfunction evidenced by depleted CoQ10 and organic acid abnormalities, compounded by sedentary behavior. Each of these patients requires a different therapeutic approach, yet conventional pain management treats them identically.

The 4-D Protocol addresses this through **individualized domain profiling** — a comprehensive assessment that integrates laboratory biomarkers (vitamin and mineral levels, hs-CRP, homocysteine, methylmalonic acid, Omega-3 Index, and others), validated symptom surveys (CSI, FIQR), underlying medical conditions, and lifestyle domains (exercise, diet, sleep quality, and stress) to generate a unique four-domain profile for each patient. This profile identifies which domains have the greatest likely impact on that patient's pain experience and guides the selection of targeted interventions accordingly.

Nutraceutical Selection: Beyond Single-Agent Thinking

The protocol's therapeutic approach extends beyond simple nutraceutical supplementation. Efforts are made to account for potential **synergy relationships** between individual nutraceuticals engaged in the protocols, as well as interactions with co-administered prescription medications, including opioids, gabapentin, and duloxetine. This is clinically important because these medications act on the same descending modulatory pathways that the protocol's nutraceuticals target. Duloxetine, for example, exerts its analgesic effect primarily through inhibition of norepinephrine reuptake, recruiting

descending noradrenergic inhibitory pathways — and its therapeutic action requires an intact opioid system.[13][14][15] Gabapentin and pregabalin not only inhibit presynaptic calcium channel trafficking but also trigger descending noradrenergic pathways that produce analgesia via spinal α2-adrenergic receptors.[13][14][15] Opioids modulate descending controls in the brainstem, switching the balance from facilitation to inhibition.[13] Understanding these mechanistic overlaps allows the protocol to position nutraceuticals as complementary agents that support and enhance the efficacy of conventional pharmacotherapy rather than competing with it.

The compilation of all these variables — domain profile, pain condition, co-administered medications, lifestyle factors, and nutraceutical synergies — is taken into account to propose the use of specific nutraceuticals best suited for each patient's unique clinical picture. Patients are then introduced to nutraceuticals in a **stepwise fashion** based on their initial profile and their subsequent response to treatment at each level. These interventions also include assessment of lifestyle profiles and recommended lifestyle interventions when indicated, with clinical decision rules that determine whether lifestyle modification alone should be attempted first or whether concurrent nutraceutical therapy is warranted.

The Novelty of the 4-D Protocol

The 4-D Protocol represents a novel approach on two fronts. First, it provides a structured, quantifiable method for assessing an individual's chronic pain based on individualized domain profiling — moving beyond subjective pain scales to incorporate objective biomarkers, validated instruments, and lifestyle assessment into a unified scoring system. Second, it offers a therapeutic framework that considers not just the four pathogenic domains and the patient's pain condition, but also the impact of selected nutraceuticals on pain processing pathways — the descending modulatory systems, glial cell activation, kynurenine pathway metabolism, and mitochondrial bioenergetics that determine how pain signals are amplified or suppressed independent of the pain condition itself.

Nijs et al. (2020) have called attention to the "inconvenient truth" that lifestyle factors across the lifespan — including physical inactivity, poor diet, sleep disruption, and chronic stress — are major but under-addressed contributors to chronic pain.[16][17] The same group's 2024 state-of-the-art perspective identifies personalized multimodal lifestyle intervention as the "best-evidenced treatment for chronic pain," yet acknowledges that current management options often fail to address lifestyle factors in a personalized, multimodal fashion.[17] A 2026 narrative review in the Clinical Journal of Pain positions chronic pain as a "systems disease requiring integrated, mechanism-based, and person-centered care," and argues that the shared biological scaffold of chronic pain "clarifies why traditional symptom-focused treatments frequently fail."[18]

The 4-D Protocol was developed to fill precisely this gap — translating the biopsychosocial model, the biomarker evidence, and the lifestyle medicine evidence into a practical, reproducible clinical workflow that can be implemented in outpatient pain management practice.

The goals of engaging the 4-D protocol with patients include enhancing their understanding of the complexities of their pain experience while emphasizing the need for lifestyle intervention and how such interventions can improve their pain experience. With this understanding will come greater motivation for patients to improve their diet and exercise activities that will support the improvement of their pain experience.

Additionally, the inclusion of the nutraceuticals incorporated by the 4-D protocols to improve patient’s pain experience will allow for less reliance on their use of opioids and facilitate the patient's ability to

taper or discontinue the use of opioids as they engage this inclusive approach to their pain management.

Finally, by introducing the 4-D protocol to patients with chronic pain *prior* to initiating opioid management should greatly reduce the number of patients relying on opioids.

The 20 Nutraceuticals:

1. Acetyl-L-Carnitine (ALC)
2. Alpha-Lipoic Acid (ALA)
3. Boswellia
4. CoQ10
5. Curcumin
6. Magnesium
7. Melatonin
8. NAC (N-Acetyl Cysteine)
9. Nicotinamide Riboside (NR) NAD+ precursors
10. Omega-3 (EPA/DHA)
11. PEA (Palmitoylethanolamide)
12. Quercetin
13. Resveratrol
14. Sulforaphane
15. Taurine
16. B-complex vitamins, including vitamin B12
17. Vitamin D3
18. P5P
19. D-Riboside
20. Agmatine

References

1. Diet Composition's Effect on Chronic Musculoskeletal Pain: A Narrative Review. Kurapatti M, Carreira D. Pain Physician. 2023;26(7):527-534.
2. Healthy Dietary Indices and Noncancer Pain: A Systematic Review of Cross-Sectional and Longitudinal Studies. Chand RR, Blyth FM, Khalatbari-Soltani S. Pain. 2023;164(4):e177-e189. doi:10.1097/j.pain.0000000000002777.
3. Diet and Chronic Non-Cancer Pain: The State of the Art and Future Directions. Brain K, Burrows TL, Bruggink L, et al. Journal of Clinical Medicine. 2021;10(21):5203. doi:10.3390/jcm10215203.
4. Dietary Interventions Are Beneficial for Patients With Chronic Pain: A Systematic Review With Meta-Analysis. Field R, Pourkazemi F, Turton J, Rooney K. Pain Medicine (Malden, Mass.). 2021;22(3):694-714. doi:10.1093/pm/pnaa378.
5. Nutrition and chronic musculoskeletal pain: A narrative review and directions for temporomandibular disorder research and management. Mesquita MLM, Magalhães AKPG, Nascimento MV, et al. Journal of Oral Rehabilitation. 2024;51(9):1925-1931. doi:10.1111/joor.13744.
6. Does Diet Play a Role in Reducing Nociception Related to Inflammation and Chronic Pain?. Bjørklund G, Aaseth J, Doşa MD, et al. Nutrition (Burbank, Los Angeles County, Calif.). 2019;66:153-165. doi:10.1016/j.nut.2019.04.007.

7. The Role of Descending Pain Modulation in Chronic Primary Pain: Potential Application of Drugs Targeting Serotonergic System. Tao ZY, Wang PX, Wei SQ, et al. Neural Plasticity. 2019;2019:1389296. doi:10.1155/2019/1389296.
8. Brainstem Pain-Control Circuitry Connectivity in Chronic Neuropathic Pain. Mills EP, Di Pietro F, Alshelh Z, et al. The Journal of Neuroscience : The Official Journal of the Society for Neuroscience. 2018;38(2):465-473. doi:10.1523/JNEUROSCI.1647-17.2017.
9. The Plasticity of Descending Controls in Pain: Translational Probing. Bannister K, Dickenson AH. The Journal of Physiology. 2017;595(13):4159-4166. doi:10.1113/JP274165.
10. Monoaminergic Mediation of Hyperalgesic and Analgesic Descending Control of Nociception in Mice. Nemoto W, Kozak D, Sotocinal SG, et al. Pain. 2023;164(5):1096-1105. doi:10.1097/j.pain.0000000000002806.
11. The Periaqueductal Gray in Chronic Low Back Pain: Dysregulated Neurotransmitters and Function. Sirucek L, De Schoenmacker I, Gorrell LM, et al. Pain. 2025;166(7):1690-1705. doi:10.1097/j.pain.0000000000003617.
12. Evaluating Associations and Contributing Factors of Descending Pain Modulation and Autonomic Nervous System Activity in Chronic and Nonchronic Knee Pain. Uzawa H, Takeshima K, Otani T, Nishida Y. Pain Physician. 2025;28(4):E437-E444.
13. Combination Pharmacotherapy for Management of Chronic Pain: From Bench to Bedside. Gilron I, Jensen TS, Dickenson AH. The Lancet. Neurology. 2013;12(11):1084-95. doi:10.1016/S1474-4422(13)70193-5.
14. Antidepressants and Gabapentinoids in Neuropathic Pain: Mechanistic Insights. Kremer M, Salvat E, Muller A, Yalcin I, Barrot M. Neuroscience. 2016;338:183-206. doi:10.1016/j.neuroscience.2016.06.057.
15. Descending Monoaminergic Pain Modulation: Bidirectional Control and Clinical Relevance. Benarroch EE. Neurology. 2008;71(3):217-21. doi:10.1212/01.wnl.0000318225.51122.63.
16. Nutritional Intervention in Chronic Pain: An Innovative Way of Targeting Central Nervous System Sensitization?. Nijs J, Tumkaya Yilmaz S, Elma Ö, et al. Expert Opinion on Therapeutic Targets. 2020;24(8):793-803. doi:10.1080/14728222.2020.1784142.
17. Personalized Multimodal Lifestyle Intervention as the Best-Evidenced Treatment for Chronic Pain: State-of-the-Art Clinical Perspective. Nijs J, Malfliet A, Roose E, et al. Journal of Clinical Medicine. 2024;13(3):644. doi:10.3390/jcm13030644.
18. Pathophysiology of Chronic Pain. Lyndon S. The Clinical Journal of Pain. 2026;42(6):e1362. doi:10.1097/AJP.0000000000001362.